--- title: "Cyclazodone: Dosing & Vendor Prices — BodyHackGuide" description: "Cyclazodone: dosing protocols, mechanism & side effects. Compare 1 verified vendor prices." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "Cyclazodone" } ] }, { "@context": "https://schema.org", "@type": "Product", "name": "Cyclazodone", "description": "Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant. It was made during the 1960s and investigated for stimulant and appetite-suppressing activity, but it was never approved for therapeutic use anywhere and no peer-reviewed report of that program was found. It carries an international nonproprietary name, which is why chemical databases list it as cyclazodone and ciclazodona, but a name is not an approval. It reached the research chemical market decades later and is now sold as a powder, a solution and an aerosol spray. There is no published receptor binding or transporter data for cyclazodone itself. Its assumed mechanism comes entirely from its parent compound: pemoline is described as a presynaptic releaser and reuptake blocker of dopamine, was used for attention deficit hyperactivity disorder, and was withdrawn from the market over rare idiosyncratic liver injury (PMID: 42188000). Whether the cyclopropyl group changes potency, selectivity or duration has not been measured in any published assay. What the modern literature does contain is metabolism. A toxicokinetic study published in 2026 examined N-methyl-cyclazodone, a newer market compound first reported in the United States in 2022 in a suspected intoxication case, and found that it is converted to cyclazodone by N-demethylation in pooled human liver S9 fraction and in male Wistar rats given a single 2 mg/kg oral dose. The reaction was driven mainly by CYP2A6 with smaller contributions from CYP1A2 and CYP2C19, and the dosed N-methyl compound was itself partly excreted unchanged in rat urine, which the authors compared with pemoline excretion in humans (PMID: 42188000). Plasma protein binding was low to moderate at about 36 percent, so protein binding interactions are unlikely. The authors note that people with reduced CYP2A6 activity, or taking CYP2A6 inhibitors, would clear the compound differently. Cyclazodone also turns up in analytical work at doping control laboratories, where it was one of eleven stimulants used to develop a hydrogen and deuterium exchange method by gas chromatography with electrospray ionization mass spectrometry (PMID: 29058415). That shows laboratories can identify it. It does not show that it is prohibited, or that it works. The safety picture is the part worth reading twice. There is no human safety data for cyclazodone, no published animal toxicology study, and no pharmacokinetic study in people. The nearest signal is the pemoline record: pemoline has caused acute liver failure requiring transplantation (PMID: 12132793) and is named among the psychotropic drugs with the highest hepatotoxic potential (PMID: 22133982). A closely related structure does not guarantee the same liability, but it is the only relevant evidence available and it points in an uncomfortable direction. Cyclazodone has no FDA or EMA authorization and is a research-use-only compound in the US market.", "url": "https://www.bodyhackguide.co/compound/cyclazodone", "image": "https://www.bodyhackguide.co/og-image.png", "brand": { "@type": "Brand", "name": "Research Compound" }, "offers": { "@type": "AggregateOffer", "lowPrice": "54.99", "highPrice": "54.99", "priceCurrency": "USD", "offerCount": "1", "availability": "https://schema.org/InStock", "offers": [ { "@type": "Offer", "price": "54.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://disguisedalpha.com/product/cyclazodoneaerosol/?coupon=reddit", "seller": { "@type": "Organization", "name": "Disguised Alpha", "url": "https://disguisedalpha.com/?coupon=reddit" } } ] } }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Cyclazodone", "description": "Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant. It was made during the 1960s and investigated for stimulant and appetite-suppressing activity, but it was never approved for therapeutic use anywhere and no peer-reviewed report of that program was found. It carries an international nonproprietary name, which is why chemical databases list it as cyclazodone and ciclazodona, but a name is not an approval. It reached the research chemical market decades later and is now sold as a powder, a solution and an aerosol spray. There is no published receptor binding or transporter data for cyclazodone itself. Its assumed mechanism comes entirely from its parent compound: pemoline is described as a presynaptic releaser and reuptake blocker of dopamine, was used for attention deficit hyperactivity disorder, and was withdrawn from the market over rare idiosyncratic liver injury (PMID: 42188000). Whether the cyclopropyl group changes potency, selectivity or duration has not been measured in any published assay. What the modern literature does contain is metabolism. A toxicokinetic study published in 2026 examined N-methyl-cyclazodone, a newer market compound first reported in the United States in 2022 in a suspected intoxication case, and found that it is converted to cyclazodone by N-demethylation in pooled human liver S9 fraction and in male Wistar rats given a single 2 mg/kg oral dose. The reaction was driven mainly by CYP2A6 with smaller contributions from CYP1A2 and CYP2C19, and the dosed N-methyl compound was itself partly excreted unchanged in rat urine, which the authors compared with pemoline excretion in humans (PMID: 42188000). Plasma protein binding was low to moderate at about 36 percent, so protein binding interactions are unlikely. The authors note that people with reduced CYP2A6 activity, or taking CYP2A6 inhibitors, would clear the compound differently. Cyclazodone also turns up in analytical work at doping control laboratories, where it was one of eleven stimulants used to develop a hydrogen and deuterium exchange method by gas chromatography with electrospray ionization mass spectrometry (PMID: 29058415). That shows laboratories can identify it. It does not show that it is prohibited, or that it works. The safety picture is the part worth reading twice. There is no human safety data for cyclazodone, no published animal toxicology study, and no pharmacokinetic study in people. The nearest signal is the pemoline record: pemoline has caused acute liver failure requiring transplantation (PMID: 12132793) and is named among the psychotropic drugs with the highest hepatotoxic potential (PMID: 22133982). A closely related structure does not guarantee the same liability, but it is the only relevant evidence available and it points in an uncomfortable direction. Cyclazodone has no FDA or EMA authorization and is a research-use-only compound in the US market.", "lastReviewed": "2026-09-07T04:46:52.679Z", "url": "https://www.bodyhackguide.co/compound/cyclazodone", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "Cyclazodone", "alternateName": [ "N-cyclopropylpemoline", "Cyclopropylpemoline", "Ciclazodona", "Cyclazodonum", "2-(cyclopropylimino)-5-phenyl-1,3-oxazolidin-4-one" ], "description": "Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant. It was made during the 1960s and investigated for stimulant and appetite-suppressing activity, but it was never approved for therapeutic use anywhere and no peer-reviewed report of that program was found. It carries an international nonproprietary name, which is why chemical databases list it as cyclazodone and ciclazodona, but a name is not an approval. It reached the research chemical market decades later and is now sold as a powder, a solution and an aerosol spray. There is no published receptor binding or transporter data for cyclazodone itself. Its assumed mechanism comes entirely from its parent compound: pemoline is described as a presynaptic releaser and reuptake blocker of dopamine, was used for attention deficit hyperactivity disorder, and was withdrawn from the market over rare idiosyncratic liver injury (PMID: 42188000). Whether the cyclopropyl group changes potency, selectivity or duration has not been measured in any published assay. What the modern literature does contain is metabolism. A toxicokinetic study published in 2026 examined N-methyl-cyclazodone, a newer market compound first reported in the United States in 2022 in a suspected intoxication case, and found that it is converted to cyclazodone by N-demethylation in pooled human liver S9 fraction and in male Wistar rats given a single 2 mg/kg oral dose. The reaction was driven mainly by CYP2A6 with smaller contributions from CYP1A2 and CYP2C19, and the dosed N-methyl compound was itself partly excreted unchanged in rat urine, which the authors compared with pemoline excretion in humans (PMID: 42188000). Plasma protein binding was low to moderate at about 36 percent, so protein binding interactions are unlikely. The authors note that people with reduced CYP2A6 activity, or taking CYP2A6 inhibitors, would clear the compound differently. Cyclazodone also turns up in analytical work at doping control laboratories, where it was one of eleven stimulants used to develop a hydrogen and deuterium exchange method by gas chromatography with electrospray ionization mass spectrometry (PMID: 29058415). That shows laboratories can identify it. It does not show that it is prohibited, or that it works. The safety picture is the part worth reading twice. There is no human safety data for cyclazodone, no published animal toxicology study, and no pharmacokinetic study in people. The nearest signal is the pemoline record: pemoline has caused acute liver failure requiring transplantation (PMID: 12132793) and is named among the psychotropic drugs with the highest hepatotoxic potential (PMID: 22133982). A closely related structure does not guarantee the same liability, but it is the only relevant evidence available and it points in an uncomfortable direction. Cyclazodone has no FDA or EMA authorization and is a research-use-only compound in the US market.", "activeIngredient": "Cyclazodone", "administrationRoute": "Oral (route used in the published animal metabolism work), Sold on the research chemical market as a solution and as an aerosol spray", "mechanismOfAction": "No receptor binding or transporter data have been published for cyclazodone. It is the N-cyclopropyl derivative of pemoline and belongs to the 4-oxazolidinone stimulant group; pemoline is described as a presynaptic releaser and reuptake blocker of dopamine (PMID: 42188000), and cyclazodone is assumed to act the same way without direct measurement. Metabolism gives the clearest handle on the molecule: in pooled human liver S9 fraction and in rat urine, N-methyl-cyclazodone is converted to cyclazodone by N-demethylation, a reaction driven mainly by CYP2A6 with smaller contributions from CYP1A2 and CYP2C19, and the dosed N-methyl compound was itself partly excreted unchanged in rat urine, which the authors compared with pemoline excretion in humans (PMID: 42188000). Plasma protein binding of the N-methyl compound was low to moderate at about 36 percent (PMID: 42188000).", "dosageForm": "nasal_spray", "legalStatus": "Not approved for human use — research chemical", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is Cyclazodone used for in research?", "acceptedAnswer": { "@type": "Answer", "text": "Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant. It was made during the 1960s and investigated for stimulant and appetite-suppressing activity, but it was never approved for therapeutic use anywhere and no peer-reviewed report of that program was found. It carries an international nonproprietary name, which is why chemical databases list it as cyclazodone and ciclazodona, but a name is not an approval. It reached the research chemical market decades later and is now sold as a powder, a solution and an aerosol spray. There is no published receptor binding or transporter data for cyclazodone itself. Its assumed mechanism comes entirely from its parent compound: pemoline is described as a presynaptic releaser and reuptake blocker of dopamine, was used for attention deficit hyperactivity disorder, and was withdrawn from the market over rare idiosyncratic liver injury (PMID: 42188000). Whether the cyclopropyl group changes potency, selectivity or duration has not been measured in any published assay. What the modern literature does contain is metabolism. A toxicokinetic study published in 2026 examined N-methyl-cyclazodone, a newer market compound first reported in the United States in 2022 in a suspected intoxication case, and found that it is converted to cyclazodone by N-demethylation in pooled human liver S9 fraction and in male Wistar rats given a single 2 mg/kg oral dose. The reaction was driven mainly by CYP2A6 with smaller contributions from CYP1A2 and CYP2C19, and the dosed N-methyl compound was itself partly excreted unchanged in rat urine, which the authors compared with pemoline excretion in humans (PMID: 42188000). Plasma protein binding was low to moderate at about 36 percent, so protein binding interactions are unlikely. The authors note that people with reduced CYP2A6 activity, or taking CYP2A6 inhibitors, would clear the compound differently. Cyclazodone also turns up in analytical work at doping control laboratories, where it was one of eleven stimulants used to develop a hydrogen and deuterium exchange method by gas chromatography with electrospray ionization mass spectrometry (PMID: 29058415). That shows laboratories can identify it. It does not show that it is prohibited, or that it works. The safety picture is the part worth reading twice. There is no human safety data for cyclazodone, no published animal toxicology study, and no pharmacokinetic study in people. The nearest signal is the pemoline record: pemoline has caused acute liver failure requiring transplantation (PMID: 12132793) and is named among the psychotropic drugs with the highest hepatotoxic potential (PMID: 22133982). A closely related structure does not guarantee the same liability, but it is the only relevant evidence available and it points in an uncomfortable direction. Cyclazodone has no FDA or EMA authorization and is a research-use-only compound in the US market." } }, { "@type": "Question", "name": "What forms does Cyclazodone come in?", "acceptedAnswer": { "@type": "Answer", "text": "Cyclazodone is available in nasal_spray form." } }, { "@type": "Question", "name": "How much does Cyclazodone cost?", "acceptedAnswer": { "@type": "Answer", "text": "Prices start at $54.99 across 1 verified vendor." } }, { "@type": "Question", "name": "How do I compare Cyclazodone vendors?", "acceptedAnswer": { "@type": "Answer", "text": "Compare prices, payment methods, shipping, and COA scores across 1 vendor." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] --- [Skip to content](#main-content) ## Research Use Only This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy). I'm 21+ — Enter SiteLeave site [![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/) [Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools) Learn Community Search ⌘K [Sign In](/auth?returnTo=%2Fcompound%2Fcyclazodone) 100K+ researchers trust BodyHackGuide — Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) 1. [Home](/) 2. [Compounds](/compare) 3. Cyclazodone [Where to buy Cyclazodone](/buy/cyclazodone) [Cyclazodone coupon codes](/coupons/cyclazodone) [Cyclazodone protocol](/protocol/cyclazodone) [Alternatives to Cyclazodone](/alternatives-to/cyclazodone) [Cyclazodone side effects](/side-effects/cyclazodone) 1. [Home](/) 3. [Compounds](/compare) 5. Cyclazodone ![Cyclazodone molecular structure](/assets/peptide-structure-placeholder-DUmZBF_j.png) # Cyclazodone Nootropics Preclinical Download PDF Also known as: N-cyclopropylpemoline, Cyclopropylpemoline, Ciclazodona, Cyclazodonum, 2-(cyclopropylimino)-5-phenyl-1,3-oxazolidin-4-one Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant. It was made during the 1960s and investigated for stimulant and appetite-suppressing activity, but it was never approved for therapeutic use anywhere and no peer-reviewed report of that program was found. Route: Oral (route used in the published animal metabolism work), Sold on the research chemical market as a solution and as an aerosol spray MW: 216.24 g/mol CAS: 14461-91-7 Last reviewed: Sep 7, 2026 [ Nootropics Category ](/wiki#cat-nootropics) Preclinical Research Stage OverviewChemical InfoDosing & ProtocolsInteractionsResearchCompare Prices1 Related ## Overview ### Best Price Available ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $54.99 1 aerosol spray · nasal\_spray [Buy Now](https://disguisedalpha.com/product/cyclazodoneaerosol/?coupon=reddit) Compare 1 vendor ### At A Glance Mechanism No receptor binding or transporter data have been published for cyclazodone. It is the N-cyclopropyl derivative of pemoline and belongs to the 4-oxazolidinone stimulant group; pemoline is described as a presynaptic releaser and reuptake blocker of dopamine (PMID: 42188000), and c… Routes Oral (route used in the published animal metabolism work) Sold on the research chemical market as a solution and as an aerosol spray Potential Benefits Stimulant and appetite-suppressing activity described from the 1960s development program, reported second hand in the modern literature without species or study detail (PMID: 42188000) Formed in vivo as the N-desmethyl metabolite of N-methyl-cyclazodone in male Wistar rats and in pooled human liver S9 fraction (PMID: 42188000) Identifiable in doping control stimulant panels by gas chromatography mass spectrometry, so laboratory confirmation of exposure is possible (PMID: 29058415) ### Overview Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant. It was made during the 1960s and investigated for stimulant and appetite-suppressing activity, but it was never approved for therapeutic use anywhere and no peer-reviewed report of that program was found. It carries an international nonproprietary name, which is why chemical databases list it as cyclazodone and ciclazodona, but a name is not an approval. It reached the research chemical market decades later and is now sold as a powder, a solution and an aerosol spray. There is no published receptor binding or transporter data for cyclazodone itself. Its assumed mechanism comes entirely from its parent compound: pemoline is described as a presynaptic releaser and reuptake blocker of dopamine, was used for attention deficit hyperactivity disorder, and was withdrawn from the market over rare idiosyncratic liver injury (PMID: 42188000). Whether the cyclopropyl group changes potency, selectivity or duration has not been measured in any published assay. What the modern literature does contain is metabolism. A toxicokinetic study published in 2026 examined N-methyl-cyclazodone, a newer market compound first reported in the United States in 2022 in a suspected intoxication case, and found that it is converted to cyclazodone by N-demethylation in pooled human liver S9 fraction and in male Wistar rats given a single 2 mg/kg oral dose. The reaction was driven mainly by CYP2A6 with smaller contributions from CYP1A2 and CYP2C19, and the dosed N-methyl compound was itself partly excreted unchanged in rat urine, which the authors compared with pemoline excretion in humans (PMID: 42188000). Plasma protein binding was low to moderate at about 36 percent, so protein binding interactions are unlikely. The authors note that people with reduced CYP2A6 activity, or taking CYP2A6 inhibitors, would clear the compound differently. Cyclazodone also turns up in analytical work at doping control laboratories, where it was one of eleven stimulants used to develop a hydrogen and deuterium exchange method by gas chromatography with electrospray ionization mass spectrometry (PMID: 29058415). That shows laboratories can identify it. It does not show that it is prohibited, or that it works. The safety picture is the part worth reading twice. There is no human safety data for cyclazodone, no published animal toxicology study, and no pharmacokinetic study in people. The nearest signal is the pemoline record: pemoline has caused acute liver failure requiring transplantation (PMID: 12132793) and is named among the psychotropic drugs with the highest hepatotoxic potential (PMID: 22133982). A closely related structure does not guarantee the same liability, but it is the only relevant evidence available and it points in an uncomfortable direction. Cyclazodone has no FDA or EMA authorization and is a research-use-only compound in the US market. ### Potential Research Fields Stimulants New psychoactive substances Forensic toxicology Drug metabolism ## Chemical Information IUPAC Name Not yet available CAS Number 14461-91-7 Molecular Formula C12H12N2O2 Molecular Mass 216.24 g/mol ![Cyclazodone molecular structure](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/135438121/PNG) [View on PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/135438121) ## Dosing & Protocols ### Unlock Dosing Protocols Free account gets you: - View beginner, intermediate & advanced protocols - See weight-based dosing calculations - Access cycle length & frequency data [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Research ### Unlock Research Data Free account gets you: - Browse PubMed study summaries - See clinical trial phases & results - Access mechanism of action details [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Interactions ### Contraindications None established by study; the following are mechanism-based or based on the parent compound. The pemoline scaffold carries a documented risk of idiosyncratic liver injury (PMID: 12132793, PMID: 22133982), so pre-existing liver disease or concurrent hepatotoxic drugs are a mechanism-based concern. Formation and clearance in the N-methyl series depends on CYP2A6, so genetic variation in that enzyme or use of CYP2A6 inhibitors would change exposure (PMID: 42188000). No pregnancy, cardiovascular or psychiatric safety data exist. Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. Best Price $54.99 Best $/mg — Vendors 1 Listings 1 nasal\_spray [Sign in for alerts ](/auth) Form Allnasal\_spray Sort Price $/mg Vendor Vendor Product Form Qty Price $/mg Coupon ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) [Disguised Alpha](/vendor/disguised-alpha) [50 ](/vendor-trust-scorecard) 🇺🇸 US 🇪🇺 EU 🇬🇧 UK Cyclazodone aerosol spray nasal\_spray 1 aerosol spray ● In Stock $54.99 BEST — — [Buy](https://disguisedalpha.com/product/cyclazodoneaerosol/?coupon=reddit) Get Cyclazodone Price Drop Alerts Set a target price and we'll notify you when any vendor drops below it. Current lowest: $54.99 [Sign in to set alerts](/auth) ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Cyclazodone. [Sign in](/auth) Current low $54.99 as of Sep 7, 2026 7-day low $54.99 30-day low $54.99 30-day change — baseline building Tracking since Sep 7, 2026 · 1 data point ### Vendors Selling Cyclazodone [ ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) #### Disguised Alpha 1 listing · from $54.99 ](/vendor/disguised-alpha) How we score these vendors Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. [View Scorecard](/vendors/scorecard) ### Related Compounds [View All](/wiki) [ ### 9-Me-BC (9-Methyl-β-carboline) Nootropics Preclinical 9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition \[PMID:17913302, PMID:20374418, PMID:32285253\]. t½ Not characterized in humans (no pharmacokinetic data). Community/anecdotal only: ~5-25 mg per day, oral. No validated or approved human dose exists. 6 studies View Profile ](/compound/9-mbc)[ ### Aniracetam Nootropics Approved (Italy) Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057. t½ About half an hour for the parent drug in humans. Plasma elimination half-life was 0.47 to 0.49 hours after a single 400 mg oral dose in 20 healthy male volunteers (PMID: 19025058). Aniracetam is extensively metabolized to N-anisoyl-GABA and anisic acid; in six elderly hospitalized patients with cerebrovascular disease and reduced creatinine clearance, metabolite half-life was 4 to 7 times longer than in young volunteers (PMID: 9062694). Preclinical View Profile ](/compound/aniracetam)[ ### Bemethyl (bemitil) Nootropics Approved (Russia) Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt. t½ Not established in humans; in healthy volunteers given a single 250 mg oral dose of the Metaprot capsule form, peak serum ethylthiobenzimidazole averaged 0.91 microg/mL at about 1.06 h, and no terminal half-life was reported (PMID: 21870773) Preclinical View Profile ](/compound/bemethyl)[ ### Bromantane Nootropics Russia Approved Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten. 34 studies View Profile ](/compound/bromantane)[ ### Dihexa Nootropics Preclinical Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University. t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. 5 to 40 mg oral per day (anecdotal range; no established human dose) 1 studies View Profile ](/compound/dihexa)[ ### Fasoracetam (NS-105) Nootropics Phase 2 Fasoracetam is a racetam developed by Nippon Shinyaku in Japan under the code NS-105 and taken into clinical development for vascular dementia. t½ Mean terminal half-life 4.82 hours, range 4.06 to 6.99 hours, after single oral doses in adolescents aged 12 to 17, with the drug excreted for the most part unchanged through the kidneys (PMID: 29339723). After intravenous dosing in animals, elimination half-life was 0.67 hours in rats, 2.1 hours in dogs and 1.3 hours in monkeys, with high systemic availability after oral dosing in all three species (PMID: 10604039). Preclinical View Profile ](/compound/fasoracetam) [ View Full Dosage Guide → Protocols, calculator & safety for Cyclazodone ](/guides/dosage/cyclazodone) ### Best Price ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $54.99 [Buy Now](https://disguisedalpha.com/product/cyclazodoneaerosol/?coupon=reddit) 1 vendors · 1 listings ### Research Score 30 0 PubMed studies ### Quality Indicators Data Completeness 63% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Studies Interactions Vendor Listings ### Quick Facts Molecular Weight 216.24 g/mol Administration Oral (route used in the published animal metabolism work), Sold on the research chemical market as a solution and as an aerosol spray CAS Number 14461-91-7 Trial Phase Preclinical 0 [Full Dosage Guide](/guides/dosage/cyclazodone)[Calculate Your Dose](/tools/reconstitution) Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions What is Cyclazodone used for in research? Cyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant. It was made during the 1960s and investigated for stimulant and appetite-suppressing activity, but it was never approved for therapeutic use anywhere and no peer-reviewed report of that program was found. It carries an international nonproprietary name, which is why chemical databases list it as cyclazodone and ciclazodona, but a name is not an approval. It reached the research chemical market decades later and is now sold as a powder, a solution and an aerosol spray. There is no published receptor binding or transporter data for cyclazodone itself. Its assumed mechanism comes entirely from its parent compound: pemoline is described as a presynaptic releaser and reuptake blocker of dopamine, was used for attention deficit hyperactivity disorder, and was withdrawn from the market over rare idiosyncratic liver injury (PMID: 42188000). Whether the cyclopropyl group changes potency, selectivity or duration has not been measured in any published assay. What the modern literature does contain is metabolism. A toxicokinetic study published in 2026 examined N-methyl-cyclazodone, a newer market compound first reported in the United States in 2022 in a suspected intoxication case, and found that it is converted to cyclazodone by N-demethylation in pooled human liver S9 fraction and in male Wistar rats given a single 2 mg/kg oral dose. The reaction was driven mainly by CYP2A6 with smaller contributions from CYP1A2 and CYP2C19, and the dosed N-methyl compound was itself partly excreted unchanged in rat urine, which the authors compared with pemoline excretion in humans (PMID: 42188000). Plasma protein binding was low to moderate at about 36 percent, so protein binding interactions are unlikely. The authors note that people with reduced CYP2A6 activity, or taking CYP2A6 inhibitors, would clear the compound differently. Cyclazodone also turns up in analytical work at doping control laboratories, where it was one of eleven stimulants used to develop a hydrogen and deuterium exchange method by gas chromatography with electrospray ionization mass spectrometry (PMID: 29058415). That shows laboratories can identify it. It does not show that it is prohibited, or that it works. The safety picture is the part worth reading twice. There is no human safety data for cyclazodone, no published animal toxicology study, and no pharmacokinetic study in people. The nearest signal is the pemoline record: pemoline has caused acute liver failure requiring transplantation (PMID: 12132793) and is named among the psychotropic drugs with the highest hepatotoxic potential (PMID: 22133982). A closely related structure does not guarantee the same liability, but it is the only relevant evidence available and it points in an uncomfortable direction. Cyclazodone has no FDA or EMA authorization and is a research-use-only compound in the US market. What forms does Cyclazodone come in? Cyclazodone is available in nasal\_spray form. How much does Cyclazodone cost? Prices start at $54.99 across 1 verified vendor. How do I compare Cyclazodone vendors? Compare prices, payment methods, shipping, and COA scores across 1 vendor. ## Research Tools [ ### Peptide Calculator Reconstitution & syringe units ](/tools/reconstitution)[ ### Reconstitution Guide How to mix, step by step ](/guides/how-to-reconstitute-peptides)[ ### Nasal Spray Calc mL per actuation ](/tools/intranasal)[ ### Half-Life Visualizer Decay curves ](/tools/halflife) ## Related Compounds [View All](/wiki) [ ### 9-Me-BC (9-Methyl-β-carboline) Nootropics Preclinical 9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition \[PMID:17913302, PMID:20374418, PMID:32285253\]. t½ Not characterized in humans (no pharmacokinetic data). Community/anecdotal only: ~5-25 mg per day, oral. No validated or approved human dose exists. 6 studies View Profile ](/compound/9-mbc)[ ### Aniracetam Nootropics Approved (Italy) Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057. t½ About half an hour for the parent drug in humans. Plasma elimination half-life was 0.47 to 0.49 hours after a single 400 mg oral dose in 20 healthy male volunteers (PMID: 19025058). Aniracetam is extensively metabolized to N-anisoyl-GABA and anisic acid; in six elderly hospitalized patients with cerebrovascular disease and reduced creatinine clearance, metabolite half-life was 4 to 7 times longer than in young volunteers (PMID: 9062694). Preclinical View Profile ](/compound/aniracetam)[ ### Bemethyl (bemitil) Nootropics Approved (Russia) Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt. t½ Not established in humans; in healthy volunteers given a single 250 mg oral dose of the Metaprot capsule form, peak serum ethylthiobenzimidazole averaged 0.91 microg/mL at about 1.06 h, and no terminal half-life was reported (PMID: 21870773) Preclinical View Profile ](/compound/bemethyl)[ ### Bromantane Nootropics Russia Approved Bromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten. 34 studies View Profile ](/compound/bromantane)[ ### Dihexa Nootropics Preclinical Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University. t½ Not characterized in humans. Dihexa was engineered for metabolic stability (resistant to plasma and enzymatic degradation) and blood-brain-barrier penetration; in preclinical work its central procognitive effects appear to outlast its plasma presence. 5 to 40 mg oral per day (anecdotal range; no established human dose) 1 studies View Profile ](/compound/dihexa)[ ### Fasoracetam (NS-105) Nootropics Phase 2 Fasoracetam is a racetam developed by Nippon Shinyaku in Japan under the code NS-105 and taken into clinical development for vascular dementia. t½ Mean terminal half-life 4.82 hours, range 4.06 to 6.99 hours, after single oral doses in adolescents aged 12 to 17, with the drug excreted for the most part unchanged through the kidneys (PMID: 29339723). After intravenous dosing in animals, elimination half-life was 0.67 hours in rats, 2.1 hours in dogs and 1.3 hours in monkeys, with high systemic availability after oral dosing in all three species (PMID: 10604039). Preclinical View Profile ](/compound/fasoracetam) Free 2026 Peptide Cheat Sheet — 50 pages, PDF Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one. [Download Free](/guides/peptide-cheat-sheet-download?utm_source=compound-cyclazodone) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. [Order Bloodwork](https://anabolicinsights.ai/?ref=nwm2zjb) ![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews. [support@bodyhackguide.co](mailto:support@bodyhackguide.co) [](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide) Explore #### Explore - [Compare prices](/compare) - [Research suppliers](/vendors) - [Deals](/deals) - [Coupons](/coupons) - [Nootropics](/nootropics) - [Brain health](/brain-health) - [Blog](/blog) - [Guides](/guides) Tools #### Tools - [Reconstitution](/tools/reconstitution) - [Dosage calculator](/tools/dosage) - [Half-life visualizer](/tools/halflife) - [COA lookup](/tools/coa) - [Cost calculator](/tools/cost-calculator) - [Stack builder](/stack-builder) - [All tools →](/tools) Trust & vendors #### Trust & vendors - [Vendor directory](/vendors) - [Trust scorecard](/vendors/scorecard) - [Get BHG verified](/vendors/get-vetted) - [Scoring methodology](/vendors/methodology) - [Peptide cheatsheet](/guides/peptide-cheat-sheet-download) Company #### Company - [About](/about) - [Affiliate disclosure](/affiliate-disclosure) - [Editorial standards](/editorial-standards) - [Creators](/creators) - [Coaches](/coaches) - [Privacy](/privacy) - [Terms](/terms) - [Full site directory →](/site-directory) **Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy) hi 👋